How to evaluate a patient's response to anti-IgE
Omalizumab, an anti-immunoglobulin E antibody, is indicated in the European Union (EU) as add-on therapy for patients with severe persistent allergic asthma whose symptoms persist, despite receiving optimised treatment with high-dose inhaled corticosteroids and a long-acting beta2-agonist. In an att...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Respiratory Society
2007-09-01
|
| Series: | European Respiratory Review |
| Subjects: | |
| Online Access: | http://err.ersjournals.com/cgi/content/full/16/104/78 |